Cargando…

NMR-Based Lipid Metabolite Profiles to Predict Outcomes in Patients Undergoing Interventional Therapy for a Hepatocellular Carcinoma (HCC): A Substudy of the SORAMIC Trial

SIMPLE SUMMARY: A hepatocellular carcinoma (HCC) is the most common cause of death in patients suffering from chronic liver diseases. In order to improve the prediction of outcomes in HCC patients, there is a need for new biomarkers. This pilot study aimed at identifying serum metabolites for the pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Geyer, Thomas, Rübenthaler, Johannes, Alunni-Fabbroni, Marianna, Schinner, Regina, Weber, Sabine, Mayerle, Julia, Schiffer, Eric, Höckner, Sebastian, Malfertheiner, Peter, Ricke, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199928/
https://www.ncbi.nlm.nih.gov/pubmed/34205110
http://dx.doi.org/10.3390/cancers13112787
_version_ 1783707490518564864
author Geyer, Thomas
Rübenthaler, Johannes
Alunni-Fabbroni, Marianna
Schinner, Regina
Weber, Sabine
Mayerle, Julia
Schiffer, Eric
Höckner, Sebastian
Malfertheiner, Peter
Ricke, Jens
author_facet Geyer, Thomas
Rübenthaler, Johannes
Alunni-Fabbroni, Marianna
Schinner, Regina
Weber, Sabine
Mayerle, Julia
Schiffer, Eric
Höckner, Sebastian
Malfertheiner, Peter
Ricke, Jens
author_sort Geyer, Thomas
collection PubMed
description SIMPLE SUMMARY: A hepatocellular carcinoma (HCC) is the most common cause of death in patients suffering from chronic liver diseases. In order to improve the prediction of outcomes in HCC patients, there is a need for new biomarkers. This pilot study aimed at identifying serum metabolites for the prediction of outcomes of HCC patients using nuclear magnetic resonance (NMR) spectroscopy. This analysis revealed that high serum concentrations of myo-inositol or dimethylamine were associated with an improved overall survival. In contrast, high concentrations of total cholesterol, LDL-cholesterol and LDL particles (LDL-P) were associated with a decreased overall survival. The identification of novel biomarkers using this NMR-based technology holds promise for opening new directions in the conduction of interventional trials in HCCs. ABSTRACT: Background: This exploratory study aimed to evaluate lipidomic and metabolomic profiles in patients with early and advanced HCCs and to investigate whether certain metabolic parameters may predict the overall survival in these patients. Methods: A total of 60 patients from the prospective, randomized-controlled, multicenter phase II SORAMIC trial were included in this substudy; among them were 30 patients with an early HCC who underwent radiofrequency ablation combined with sorafenib or a placebo and 30 patients with an advanced HCC who were treated with a selective internal radiation therapy (SIRT) plus sorafenib vs. sorafenib alone. The blood serum of these patients was analyzed using a standardized nuclear magnetic resonance (NMR) platform. All tested metabolites were correlated with the overall survival. Results: The overall survival (OS) was significantly higher in patients with an early HCC (median OS: 34.0 months) compared with patients with an advanced HCC (median OS: 12.0 months) (p < 0.0001). Patients with high serum concentrations of myo-inositol (MI) had a higher overall survival compared with patients with low concentrations (21.6 vs. 13.8 months) with a Pearson correlation coefficient of 0.331 (p = 0.011). Patients with high serum concentrations of dimethylamine had a higher overall survival compared with patients with low concentrations (25.1 vs. 19.7 months) with a Pearson correlation coefficient of 0.279 (p = 0.034). High concentrations of total cholesterol, LDL-cholesterol and LDL particles (LDL-P) were associated with a decreased overall survival. Conclusions: NMR-based lipidomic and metabolomic profiling has the potential to identify individual metabolite biomarkers that predict the outcome of patients with an HCC exposed to non-invasive therapeutic management.
format Online
Article
Text
id pubmed-8199928
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81999282021-06-14 NMR-Based Lipid Metabolite Profiles to Predict Outcomes in Patients Undergoing Interventional Therapy for a Hepatocellular Carcinoma (HCC): A Substudy of the SORAMIC Trial Geyer, Thomas Rübenthaler, Johannes Alunni-Fabbroni, Marianna Schinner, Regina Weber, Sabine Mayerle, Julia Schiffer, Eric Höckner, Sebastian Malfertheiner, Peter Ricke, Jens Cancers (Basel) Article SIMPLE SUMMARY: A hepatocellular carcinoma (HCC) is the most common cause of death in patients suffering from chronic liver diseases. In order to improve the prediction of outcomes in HCC patients, there is a need for new biomarkers. This pilot study aimed at identifying serum metabolites for the prediction of outcomes of HCC patients using nuclear magnetic resonance (NMR) spectroscopy. This analysis revealed that high serum concentrations of myo-inositol or dimethylamine were associated with an improved overall survival. In contrast, high concentrations of total cholesterol, LDL-cholesterol and LDL particles (LDL-P) were associated with a decreased overall survival. The identification of novel biomarkers using this NMR-based technology holds promise for opening new directions in the conduction of interventional trials in HCCs. ABSTRACT: Background: This exploratory study aimed to evaluate lipidomic and metabolomic profiles in patients with early and advanced HCCs and to investigate whether certain metabolic parameters may predict the overall survival in these patients. Methods: A total of 60 patients from the prospective, randomized-controlled, multicenter phase II SORAMIC trial were included in this substudy; among them were 30 patients with an early HCC who underwent radiofrequency ablation combined with sorafenib or a placebo and 30 patients with an advanced HCC who were treated with a selective internal radiation therapy (SIRT) plus sorafenib vs. sorafenib alone. The blood serum of these patients was analyzed using a standardized nuclear magnetic resonance (NMR) platform. All tested metabolites were correlated with the overall survival. Results: The overall survival (OS) was significantly higher in patients with an early HCC (median OS: 34.0 months) compared with patients with an advanced HCC (median OS: 12.0 months) (p < 0.0001). Patients with high serum concentrations of myo-inositol (MI) had a higher overall survival compared with patients with low concentrations (21.6 vs. 13.8 months) with a Pearson correlation coefficient of 0.331 (p = 0.011). Patients with high serum concentrations of dimethylamine had a higher overall survival compared with patients with low concentrations (25.1 vs. 19.7 months) with a Pearson correlation coefficient of 0.279 (p = 0.034). High concentrations of total cholesterol, LDL-cholesterol and LDL particles (LDL-P) were associated with a decreased overall survival. Conclusions: NMR-based lipidomic and metabolomic profiling has the potential to identify individual metabolite biomarkers that predict the outcome of patients with an HCC exposed to non-invasive therapeutic management. MDPI 2021-06-03 /pmc/articles/PMC8199928/ /pubmed/34205110 http://dx.doi.org/10.3390/cancers13112787 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Geyer, Thomas
Rübenthaler, Johannes
Alunni-Fabbroni, Marianna
Schinner, Regina
Weber, Sabine
Mayerle, Julia
Schiffer, Eric
Höckner, Sebastian
Malfertheiner, Peter
Ricke, Jens
NMR-Based Lipid Metabolite Profiles to Predict Outcomes in Patients Undergoing Interventional Therapy for a Hepatocellular Carcinoma (HCC): A Substudy of the SORAMIC Trial
title NMR-Based Lipid Metabolite Profiles to Predict Outcomes in Patients Undergoing Interventional Therapy for a Hepatocellular Carcinoma (HCC): A Substudy of the SORAMIC Trial
title_full NMR-Based Lipid Metabolite Profiles to Predict Outcomes in Patients Undergoing Interventional Therapy for a Hepatocellular Carcinoma (HCC): A Substudy of the SORAMIC Trial
title_fullStr NMR-Based Lipid Metabolite Profiles to Predict Outcomes in Patients Undergoing Interventional Therapy for a Hepatocellular Carcinoma (HCC): A Substudy of the SORAMIC Trial
title_full_unstemmed NMR-Based Lipid Metabolite Profiles to Predict Outcomes in Patients Undergoing Interventional Therapy for a Hepatocellular Carcinoma (HCC): A Substudy of the SORAMIC Trial
title_short NMR-Based Lipid Metabolite Profiles to Predict Outcomes in Patients Undergoing Interventional Therapy for a Hepatocellular Carcinoma (HCC): A Substudy of the SORAMIC Trial
title_sort nmr-based lipid metabolite profiles to predict outcomes in patients undergoing interventional therapy for a hepatocellular carcinoma (hcc): a substudy of the soramic trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199928/
https://www.ncbi.nlm.nih.gov/pubmed/34205110
http://dx.doi.org/10.3390/cancers13112787
work_keys_str_mv AT geyerthomas nmrbasedlipidmetaboliteprofilestopredictoutcomesinpatientsundergoinginterventionaltherapyforahepatocellularcarcinomahccasubstudyofthesoramictrial
AT rubenthalerjohannes nmrbasedlipidmetaboliteprofilestopredictoutcomesinpatientsundergoinginterventionaltherapyforahepatocellularcarcinomahccasubstudyofthesoramictrial
AT alunnifabbronimarianna nmrbasedlipidmetaboliteprofilestopredictoutcomesinpatientsundergoinginterventionaltherapyforahepatocellularcarcinomahccasubstudyofthesoramictrial
AT schinnerregina nmrbasedlipidmetaboliteprofilestopredictoutcomesinpatientsundergoinginterventionaltherapyforahepatocellularcarcinomahccasubstudyofthesoramictrial
AT webersabine nmrbasedlipidmetaboliteprofilestopredictoutcomesinpatientsundergoinginterventionaltherapyforahepatocellularcarcinomahccasubstudyofthesoramictrial
AT mayerlejulia nmrbasedlipidmetaboliteprofilestopredictoutcomesinpatientsundergoinginterventionaltherapyforahepatocellularcarcinomahccasubstudyofthesoramictrial
AT schiffereric nmrbasedlipidmetaboliteprofilestopredictoutcomesinpatientsundergoinginterventionaltherapyforahepatocellularcarcinomahccasubstudyofthesoramictrial
AT hocknersebastian nmrbasedlipidmetaboliteprofilestopredictoutcomesinpatientsundergoinginterventionaltherapyforahepatocellularcarcinomahccasubstudyofthesoramictrial
AT malfertheinerpeter nmrbasedlipidmetaboliteprofilestopredictoutcomesinpatientsundergoinginterventionaltherapyforahepatocellularcarcinomahccasubstudyofthesoramictrial
AT rickejens nmrbasedlipidmetaboliteprofilestopredictoutcomesinpatientsundergoinginterventionaltherapyforahepatocellularcarcinomahccasubstudyofthesoramictrial